8-K: Context Therapeutics In-Licenses Nectin-4 Bispecific Antibody from BioAtla in $133.5 Million Deal

Context Therapeutics has secured an exclusive worldwide license from BioAtla to develop and commercialize a Nectin-4 x CD3 bispecific antibody, CT-202, for up to $133.5 million plus royalties.

Summary

• Context Therapeutics has entered into a license agreement with BioAtla for the exclusive worldwide rights to develop, manufacture, and commercialize two licensed antibodies, including BA3362, which Context has renamed CT-202.
• BioAtla will receive an upfront payment of $11 million and is eligible for up to $4 million in near-term milestones, $118.5 million in additional milestone payments, and tiered royalties on future net sales.
• The agreement includes a clause where BioAtla will refrain from competitive activities related to Nectin-4 bispecific antibodies.
• Context anticipates filing an Investigational New Drug (IND) application for CT-202 in mid-2026.
• The company expects its cash reserves as of June 30, 2024, to fund its ongoing CTIM-76 and CT-95 Phase 1a trials, expenses through the IND filing for CT-202, and operations into 2027.
• Context's CTIM-76 Phase 1 clinical trial is actively screening patients, with the first patient dosing expected in October or November 2024.
• Initial CTIM-76 Phase 1 dose escalation data is anticipated in the first half of 2026, and initial CT-95 Phase 1 dose escalation data is expected in the middle of 2026.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a significant licensing deal, pipeline expansion, and a clear path forward for clinical development. However, it also acknowledges the inherent risks and uncertainties associated with drug development, which tempers the overall sentiment.

Positives

• Context Therapeutics has expanded its pipeline with the addition of CT-202, a promising Nectin-4 x CD3 bispecific antibody.
• The company has secured exclusive worldwide rights to develop and commercialize CT-202.
• The company has a cash runway into 2027, which is expected to fund the development of its pipeline assets.
• The company is actively progressing its CTIM-76 Phase 1 trial with patient dosing expected soon.
• The company has a clear timeline for initial data readouts for its CTIM-76 and CT-95 Phase 1 trials.

Negatives

• The company is reliant on assumptions that may prove to be imprecise, and the company could utilize its available capital resources sooner than it expects.
• The company is still in the early stages of clinical development, with no products currently approved for commercial sale.
• The company is subject to the risks and uncertainties associated with clinical trials and regulatory approvals.

Risks

• The company's estimates for cash runway are based on assumptions that may be imprecise, potentially leading to earlier capital depletion.
• Clinical trial results may not be favorable, and regulatory approvals may not be granted.
• The company faces competition from other companies developing similar therapies.
• The company is dependent on the successful development and commercialization of its pipeline assets.
• The company may need to raise additional capital in the future to fund its operations.

Future Outlook

Context Therapeutics expects its current cash reserves to fund operations into 2027, including the ongoing clinical trials and the development of CT-202. The company anticipates filing an IND for CT-202 in mid-2026 and expects initial data from its CTIM-76 and CT-95 Phase 1 trials in 2026.

Management Comments

• Jay M. Short, Ph.D., CEO of BioAtla, stated that the transaction marks the first of multiple collaborations, increasing shareholder value through non-dilutive means.
• Martin Lehr, CEO of Context, said that the transaction is consistent with their focus on building a pipeline of TCE assets and that they identified BioAtla's Nectin-4 TCE antibody as a potentially best-in-class asset.

Industry Context

This announcement reflects the growing interest in T cell engaging bispecific antibodies for cancer therapy, particularly in solid tumors. The deal highlights the strategic importance of Nectin-4 as a target and the trend of companies in-licensing promising assets to expand their pipelines.

Comparison to Industry Standards

• The licensing agreement between Context and BioAtla is similar to other deals in the biotech industry, where companies acquire rights to promising drug candidates in exchange for upfront payments, milestones, and royalties.
• The upfront payment of $11 million and potential milestone payments of $122.5 million are within the typical range for licensing agreements of this type, although the specific terms vary based on the stage of development and perceived value of the asset.
• The tiered royalty structure is also a common practice in the industry, allowing the licensor to benefit from the commercial success of the product.
• The focus on T cell engagers and bispecific antibodies aligns with current trends in cancer immunotherapy, where these modalities are gaining traction due to their potential to redirect the immune system to attack cancer cells.
• The development timelines for CT-202, with an IND filing expected in mid-2026, are consistent with the typical timelines for early-stage drug development.

Stakeholder Impact

• Shareholders may view the licensing agreement positively, as it expands the company's pipeline and potential for future revenue.
• Employees may be impacted by the increased workload associated with the new program, but also by the potential for growth and success.
• Customers (patients) may benefit from the development of new therapies for solid tumors.
• Suppliers and creditors may see increased business opportunities with Context Therapeutics.

Next Steps

• Context Therapeutics will proceed with the development of CT-202, including preclinical studies and preparation for the IND filing.
• The company will continue to enroll patients in the CTIM-76 Phase 1 clinical trial and expects to dose the first patient in October or November 2024.
• Context will continue to advance its CT-95 program, with first patient dosing expected in Q1 2025.
• The company will monitor the progress of its ongoing clinical trials and provide updates on data readouts.

Key Dates

Keywords

bispecific antibody, T cell engager, Nectin-4, CT-202, CTIM-76, CT-95, clinical trial, IND, oncology, BioAtla, license agreement